glp-1 drug exposure pharmaceutical companies 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Top pharmaceuticals of H1 2025:

Description

Cardiovascular, mortality, and kidney outcomes with GLP1 receptor agonists in patients with type 2 diabetes: a systematic review and metaanalysis of randomised trials

The major clinical trials (SURPASS for diabetes, SURMOUNT for weight management) did not identify anxiety as a common adverse event

Supporting a diverse, healthy microbiome through prebiotic and probiotic-rich foods may therefore indirectly enhance GLP-1 activity, though evidence is still emerging

These figures indicate a significant change in the amount of weight people can lose with this drug

Given the cardiovascular and renal benefits of GLP-1 receptor agonists, how do these effects expand their use beyond glycemic control in patients with metabolic disorders